# HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

> **NCT07530198** · PHASE1 · RECRUITING · sponsor: **Immuno Cure Holding (HK) Limited** · enrollment: 22 (estimated)

## Conditions studied

- Human Immunodeficiency Virus
- Human Immunodeficiency Virus I Infection

## Interventions

- **BIOLOGICAL:** ICVAX (TERESA-EPT I device)
- **BIOLOGICAL:** ICVAX (PharmaJet Tropis device)
- **BIOLOGICAL:** ICVAX (TriGrid device)

## Key facts

- **NCT ID:** NCT07530198
- **Lead sponsor:** Immuno Cure Holding (HK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07530198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07530198, "HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07530198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*